| Literature DB >> 30359265 |
Qi Wu1, Si Sun2, Zhiyu Li1, Qian Yang1, Bei Li1, Shan Zhu1, Lijun Wang1, Juan Wu3, Jingping Yuan3, Changhua Yang4, Juanjuan Li5, Shengrong Sun6.
Abstract
Emerging evidence supports the pivotal roles of cancer-associated cachexia in breast cancer progression. However, the mediators and mechanisms that mediate cancer-induced cachexia remain unclear. Here, we show that breast cancer-derived exosomes alter adipocytes and muscle cells in terms of increased catabolism characterized by the release of metabolites. Likewise, tumour cells cocultivated with mature adipocytes or C2C12 exhibit an aggressive phenotype through inducing epithelial-mesenchymal transition. Mechanistically, we show that cancer cell-secreted miR-155 promotes beige/brown differentiation and remodel metabolism in resident adipocytes by downregulating the PPARγ expression, but does not significantly affect biological conversion in C2C12. In vitro the use of propranolol ameliorates tumour exosomes-associated cachectic wasting through upregulating the PPARγ expression. These results demonstrate that cancer-derived exosomes reprogram systemic energy metabolism and accelerate cancer-associated cachexia to facilitate tumour progression.Entities:
Keywords: Breast cancer; Cachexia; Exosomes; Tumour progression
Mesh:
Substances:
Year: 2018 PMID: 30359265 PMCID: PMC6201501 DOI: 10.1186/s12943-018-0899-5
Source DB: PubMed Journal: Mol Cancer ISSN: 1476-4598 Impact factor: 27.401
Fig. 1Breast cancer-derived exosomes reshape metabolic characteristics in adipocytes and skeletal muscle cells. (a) Representative immunohistochemistry staining of CD36 and FATP1. The pictures also show positive staining for FATP1 and CD36 in breast cancer tissues located near stromal adipocytes. (b) Immunofluorescence staining for myosin heavy chain 1 (MYH1) after treatment 24 h. Scale bars represent 50 μm. The C2C12 in the CytoD group were treated with cytochalasin D (final concentration, 2 μg/ml) and 50 μg of exosomes purified from cancer-associated conditioned medium (CA-CM). (c) Mature adipocytes were stained with red oil after treated by CytoD and/or exosomes. The adipocytes in the CytoD group were treated with cytochalasin D (final concentration, 2 μg/ml) and 50 μg of exosomes purified from cancer-associated conditioned medium (CA-CM). (d) The levels of secreted metabolites (pyruvate, lactate, glycerol and free fatty acids) enriched in media were determined by colorimetric assay. AD: adipocytes. (e) Raw data for the oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) as determined by the Seahorse XF24 analyser. The ECAR was evaluated after the addition of 10 mM glucose to adipocytes or C2C12 in the presence or absence of exosomes. The OCR was measured in the presence of palmitate as described in the Methods. (f) Adipocytes or C2C12 were cocultivated in the presence or absence of exosomes. The proteins were extracted for western blot analysis of the expression of the indicated proteins. Data are presented as the mean ± S.D. of at least three independent experiments. * P < 0.05 versus control values, # P < 0.05 versus control values as positive group
Fig. 2Propranolol ameliorates tumour exosomes-associated cachectic wasting in vitro. The adipocytes or C2C12 in 50 μg of exosomes purified from cancer-associated conditioned medium (CA-CM) and/or Propranolol (PRO, 10 μM). (a) Mature adipocytes in the presence or absence of exosomes and/or Propranolol were stained with red oil. (b) Adipocytes were cocultivated in the presence or absence of exosomes and/or Propranolol. After 3 days, proteins were extracted for western blot analysis of the expression of the indicated proteins. (c) Immunofluorescence staining for myosin heavy chain 1 (MYH1) after treatment 24 h. Scale bars represent 50 μm. After C2C12 cells were treated for 1 days, and Western blot analysis of related protein expression in different groups. Data are presented as the mean ± S.D. of at least three independent experiments. * P < 0.05 versus control values, # P < 0.05 versus control values as positive group
Fig. 3ExomiR-155 mediates the adipocyte metabolism by downregulating PPARγ. The adipocytes in 50 μg of exosomes purified from cancer-associated conditioned medium (CA-CM). (a) Exosomes originating from CA-CM viewed by electron microscopy (scale bar, 200 nm). (b) Exosomes from CA-CM were analysed by western blot. (c) NanoSight analysis of exosomes derived from CA-CM. (d) 4 T-1 were cocultivated in the presence or absence of adipocytes. After 3 days, exosomal miRNAs were further verified by qPCR. And RNA was extracted from the adipocytes and subjected to qPCR analysis with primers specific to mature miRNA. (e) The predicted miR-155 binding site in the 3’UTR of the PPARγ gene from TargetScan. (f) The GV272 vector containing the 3’UTR of the target gene harbouring wild-type (wt) or mutated (mt) miRNA binding sites was transfected into HEK 293 T cells stably expressing miRNA or empty vector (as a control). Luciferase activity was analysed at 48 h post-transfection, and the ratio of firefly luciferase activity to Renilla luciferase activity is shown. (g) Breast cancer cells were transfected with miRNA-155 pre-miRNA or miR-155 inhibitor, mature adipocytes were transfected with miR-155 mimic as the positive control and the control vector was applied as the negative control. Mature adipocytes cultured in the presence or absence of tumour exosomes for 3 days were stained with red oil, and Western blot analysis of related protein expression in different groups (h). Data are presented as the mean ± S.D. of at least three independent experiments. * P < 0.05 versus control values, # P < 0.05 versus control values as positive group